Really happy to attend for the first time the #AACR Special Conference on Innovations in Prostate Cancer Research & Treatment. Fantastic science and great discussions with leaders in the field. Thanks to the organisers for the amazing meeting. Back to Boston very soon!

Catching up on sharing this…Great to see the EndoCompass Research Roadmap published. A Europe-wide initiative led by @esendocrinology.bsky.social & #ESPE to align endocrine research. Grateful to have contributed on endocrine causes & consequences of cancer. 🔗bit.ly/44KIoQ2

Have you had the chance to go through the hot-off-the-press EYES News issue?🗞️ Don’t miss the amazing careers section, where we had the honour of interviewing Professor @fbeuschlein.bsky.social, who shared his career journey, insights, and advice with us. @ese-eyes.bsky.social 🔗 bit.ly/3Y44vgr

🚨The Winter issue of EYES News (Issue 24), focused on the relationship between hormones and cardiovascular health, has just been launched‼️As the year comes to an end, we send our warm wishes for a calm, restorative festive season to all our readers 🎄 @ese-eyes.bsky.social 🔗 bit.ly/4pNj7Nw

Last lab meeting of the year with the Translational Therapeutics team 🎄 Exciting data + Christmas lunch + science & Christmas quiz = the perfect way to celebrate a fantastic and productive year 🧪✨ Grateful to be part of this team 💫 @asharpmedonc.bsky.social @icr.ac.uk

Could targeting MCL1 & BCLXL be effective in advanced #ProstateCancer? Research in @cp-iscience.bsky.social led by Dr Westaby, @juanjimenezvacas.bsky.social, @asharpmedonc.bsky.social & Prof de Bono, supported by our Movember London Centre of Excellence. Grab a ☕ & read: doi.org/10.1016/j.is...

The Translational Therapeutics team is on its way to York for the Hormone-Dependent Cancers Conference! Excited to meet friends, make new ones, network, and dive into some really interesting scientific discussions. @asharpmedonc.bsky.social @socendocrinology.bsky.social

Excited to share our new study from @asharpmedonc.bsky.social lab at @icr.ac.uk 🔬✨ We identify therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer. So happy to have to co-led this work with my colleagues and friends #DanWestaby & @inesfigueiredo.bsky.social 🔗 bit.ly/4oHSvNx

It’s my first #Movember! 🥸 As a prostate cancer researcher at @icr.ac.uk (and someone whose family’s been affected by the disease), I’m growing a moustache to support awareness and research this month. 💙 Join me on this Mo journey! 👨🏻‍🔬 movember.com/m/15464015?m...

The importance of fundamental research! 🧪🧫👩‍🔬👨‍🔬

Our fantastic @prostateukprofs.bsky.social career development fellow @juanjimenezvacas.bsky.social takes a closer look at a potential new treatment approach for #ProstateCancer that has stopped responding to existing therapies ⬇️.

This was my last meeting with the @ese-eyes.bsky.social News editorial committee, the newsletter of the early career group of the @esendocrinology.bsky.social Grateful for the journey & everyone who made it special. Time to pass the torch to the next generation to keep driving it forward!

🚨 Delighted to share our latest paper, from @asharpmedonc.bsky.social team in collaboration with Johann de Bono’s team at @icr.ac.uk and international colleagues, published in Nature Communications @natureportfolio.nature.com Read here: bit.ly/477pYt7 🧵1/4

Teamwork makes the dream works! Thank you, PCUK, for your support! @prostatecanceruk.bsky.social @prostateukprofs.bsky.social

Could targeting MCL1 be a new treatment approach for hormone therapy-resistant #ProstateCancer? A study in @natcomms.nature.com by @juanjimenezvacas.bsky.social, @asharpmedonc.bsky.social and the @icr.ac.uk team explores precision therapy strategies. Grab a ☕ and read: doi.org/10.1038/s414...